FendX Technologies’ Dr Carolyn Myers Provides REPELWRAP Film Manufacturing Dunmore Partnership Update

In a recent interview with Tracy Weslosky, Dr. Carolyn Myers, President, CEO, and Director of FendX Technologies Inc. (CSE: FNDX | OTCQB: FDXTF), shared insights into the progress and strategic initiatives surrounding their groundbreaking REPELWRAP™ film, a film that significantly reduces adhesion of bacteria and viruses on surfaces. Collaborating with Dunmore International Corp., their manufacturing partner, FendX has achieved pivotal advancements in automating and refining the production process of REPELWRAP™ film, targeting efficiency enhancements such as reduced changeovers and optimized heating and drying phases. These improvements are key to streamlining production and ensuring the product is cost-effective without sacrificing performance. Dr. Myers emphasized the critical next steps involving rigorous real-world testing to confirm the film’s durability and efficacy against bacteria and viruses in varied environments, including healthcare and other high traffic venues. Such testing, previously conducted in McMaster University’s lab, demonstrated the film’s promising potential. FendX aims to transition to commercial production by the year’s end, with aspirations to begin revenue generation in the first half of 2025. The partnership with McMaster University, which facilitated the exclusive licensing of the nanotechnology IP for REPELWRAP™ film, was highlighted as instrumental in meeting developmental milestones. The strategic relationship with Dunmore was also underscored as vital for advancing the product towards commercialization. Dr. Myers exemplifies a commitment to delivering innovative solutions designed to mitigate pathogen transmission on surfaces, marking a significant leap towards enhancing public health safety.